AMGEN INC is 25.8x more valuable than ImmunityBio, Inc. by market capitalization ($191.70 B vs $7.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IBRX | AMGN |
|---|---|---|
| Market cap | $7.44 B | $191.70 B |
| US-listed rank | #1125 | #79 |
| Revenue (latest FY) | $113.29M | $36.75B |
| Net income (latest FY) | -$351.50M | $7.71B |
| Net margin | -310.3% | 21.0% |
| P/E (trailing FY) | - | 24.9 |
| SEC filings | 528 | 1,011 |
AMGEN INC is 25.8x more valuable than ImmunityBio, Inc. by market capitalization ($191.70 B vs $7.44 B).
In their latest fiscal years, ImmunityBio, Inc. reported $113.29M in revenue while AMGEN INC reported $36.75B.
Full pages: ImmunityBio, Inc. and AMGEN INC, or browse the full rankings.